About Us

Mission Statement

At DiaCarta, our mission is to improve the lives of cancer patients through innovative precision diagnostics. We are committed to providing accurate, reliable, and affordable diagnostics that help physicians make informed treatment decisions. We foster a collaborative and diverse culture that values teamwork, integrity, and excellence in everything we do. We continuously invest in research and development to push the boundaries of cancer management and bring new hope to patients and their families.

 

DiaCarta Value

Patient-Centric operations: Our mission is to provide innovative and affordable solutions for cancer patient management, and we prioritize the needs of patients and their families in everything we do.

Innovation: We are committed to advancing precision diagnostics and improving patient outcomes through cutting-edge research and development.

Accuracy and Reliability: We maintain uncompromising standards of accuracy, reliability, and reproducibility in all of our products and services to ensure the best possible outcomes for patients and healthcare providers.

Collaboration: We foster a diverse and inclusive team culture that encourages open communication, collaboration, and mutual respect, both within our organization and with our partners and customers.

Continuous Improvement: We are dedicated to ongoing improvement and innovation, and we invest in the development of our team, our products, and our infrastructure to better serve our customers and achieve our mission.

 

Compliance

We are committed to designing and manufacturing products with the good of the patient in mind. We will continuously improve our quality management systems, comply with all applicable regulatory requirements, and build customer confidence by delivering excellent products and services.

Download ISO Certificate

Leadership

President and CEO, Founder

Aiguo Zhang, Ph.D.
Founder and Consultant

Paul Okunieff, M.D.
Senior VP, Business Development

Ramanathan Vairavan, Ph.D
Senior VP of Companion Diagnostics

Hongjun (Harry) Yang, Ph.D.
Vice President of External Affairs

Anne K. Vallerga, Ph.D., MBA
VP of Finance and Principle Financial Officer

Dennis Gao
Vice President of Regulatory

King Lee, Ph.D.
Vice President of Product Management and Marketing

Wei Liu, Ph.D., MBA
Vice President, Clinical Affairs

Zheng Li, MBBS, MS
CLIA Lab Director

C. Mark Lu, M.D.
General Manager, Asia Pacific

Effie Ho, Ph.D., MBA
Sr. Director, BD & Clinical (EU)

Dr Mauro Scimia

President and CEO, Founder

Aiguo Zhang, Ph.D.

Dr. Zhang is an active entrepreneur and executive in the biotech and pharmaceutical industries with extensive experience ranging from startups to major corporations, including Panomics, Affymetrix and Bio-Rad. Dr. Zhang brings knowledge and an extensive network in Asia and Emerging Markets to his role at DiaCarta. His substantial experience in R&D management and capability building in Asia and Emerging Markets has a project scope ranging from discovery research to sales and marketing in both US and international markets. He received his Ph.D. from Simon Fraser University in molecular toxicology and pharmacology, was a postdoctoral scholar at the University of Massachusetts, and served as an assistant professor of research at the University of California, Berkeley. Dr. Zhang has published many research papers in leading scientific journals. His inventions are the subject of many patents and patent-pending applications.

Founder and Consultant

Paul Okunieff, M.D.

Dr. Paul Okunieff is board-certified in therapeutic radiology and is among the pioneers of in-vivo nuclear magnetic resonance imaging of tumors. Dr. Okunieff moved to the University of Florida in 2009 from the University of Rochester School of Medicine and Dentistry, where he served as Philip Rubin Professor in radiation oncology and chair of the department of radiation oncology. Prior to his appointment in Rochester in 1998, Dr. Okunieff served as the branch chief of radiation oncology at the National Cancer Institute and as an assistant professor in radiation oncology at Harvard Medical School between 1988 and 1993. Dr. Okunieff earned his medical degree from Harvard Medical School, where he also completed his postdoctoral fellowship in medicine and a fellowship in radiation medicine at Massachusetts General Hospital. He earned bachelor’s degrees in electrical engineering & computer science, and biological science from Massachusetts Institute of Technology. Dr. Okunieff serves as the radiation oncology chair for the Southwest Oncology Group, and a diplomat of the National Board of Medical Examiners where he serves on national committees overseeing the safety and quality of therapeutic radiation delivery.

Senior VP, Business Development

Ramanathan Vairavan, Ph.D

Ram has more than 40 years experience in the clinical diagnostics industry. He worked for Hoechst Ag/Behring Diagnostics of Germany in the US, Germany & Singapore where held various positions in research, development, operation, international sales, marketing and executive management. He co-founded Autogenomics, a biotechnology company based in Carlsbad, CA, which developed and marketed an automated multiplexing microarray platform for molecular testing using novel biofilm chip technology to perform disease signatures through genomic and proteomic profiling with tests in the area of women’s health, genetic disorders, pharmacogenomics, cancer and infectious disease. He has extensive contacts with opinion leaders in the US and Europe and has set up distribution in about 30 countries in EU, Middle East, FE and SE Asia.

Senior VP of Companion Diagnostics

Hongjun (Harry) Yang, Ph.D.

Dr. Hongjun Yang currently serves as an SVP of Companion Diagnostics at DiaCarta, Inc. Dr. Yang is a well-established, passionate and dynamic executive in biomedical and pharmaceutical industry and academia with diversified multidisciplinary background and extensive experience in Research and Development management, technology innovation, corporate development, global business development and collaboration, long-term strategic planning, quality management system (QMS), clinical trial operation (IND, CTP, HGR), and compliance with the regulations (CLIA, CAP, GXP), chemical manufacturing control (CMC), commercialization and product launching in diagnostics, therapeutics, biopharmaceutical industries and specialized in precision medicine, biomarkers & diagnostics, public health, etc.

Dr. Yang has been served as an executive at multiple startup companies and institutes in both US and China. He was the original developer of electrochemiluminescence (ECL) technology and its instrumentation which is exclusively owned by Roche diagnostics. He is a pioneer for flow-thru DNA chip technology, an initiator of global human genome HapMap program, gene expression database, NGS platform design, biomarkers and companion diagnostics for precision medicine. Dr. Yang also initiated the growth and development of Zhangjiang Biopharma Park, Shanghai, China as well as the promotion for the international collaborations between China and West Countries. Prior to the current post, Dr. Yang served as a director of personalized Healthcare and biomarkers at AstraZeneca-China, then was promoted as an executive personalized healthcare strategy leader at AstraZeneca-Global due to his outstanding performance and delivery. Recently he joined DiaCarta as SVP of companion diagnostics and he is focused on the next generation of companion diagnostics to facilitate anti-cancer drug discovery and development, and the implementation of precision medicine.

Dr. Yang has been active in various professional organizations. He is a member of American Society of Clinical Oncology (ASCO), The European Society for Medical Oncology (ESMO); He also served on the board of director of China Society of Biotechnology (CSBT) and Chinese Biopharmaceutical Association (CBA). He is the founder and founding chairman of Precision Medicine Committee in CSBT.

Vice President of External Affairs

Anne K. Vallerga, Ph.D., MBA

Anne Kathyrn Vallerga, M.A., Ph.D., M.B.A. has over 22 years of experience in bioproduct development, corporate strategy, mergers, acquisitions, and strategic business development, including identifying and out-licensing or in-licensing. This includes immunobiologics, small molecule pharmaceutical drugs, device and companion diagnostic technologies. Dr Anne Vallerga has successfully developed and subsequently sold or strategically partnered several late pre-clinical and clinical Phase I/II/III pharmaceutical and companion diagnostic assets to private and public companies. Dr. Vallerga has also successfully managed, both scientifically, financially, and operationally, a 100-million-dollar contract, 10 million-dollar-grant and several single- and double-digit multi-million-dollar collaborative therapeutic drug and device product development projects in diagnostics, medical devices, cancer, immunity, infection, allergy and regenerative medicine. Product successes have been achieved by Anne Vallerga in diagnostics/prognostics, early detection, and biomarker validation. This includes development and commercialization of an advanced instrumented diagnostic devices and reagent kit products that received US approvals and are in uses today. Dr. Vallerga also has led or been an important part of teams that developed lymphatic drug-delivery/diagnostic device systems for intratumoral or intralymphatic diagnostic and companion therapeutic products, for example used in combination with immunotherapy, radiotherapy and/or chemotherapy for cancer or other patients.  Dr. Vallerga previously led drug, diagnostic and device product development as President of Colby Pharmaceutical Company, Executive Vice President Pangene Corporation and was the Diagnostics Program Group Leader within SRI International (formerly Stanford Research Institute) Pharmaceutical Drug Development Division. She also was employed as an important member of the Stanford University Medical School Institutional Review Board (IRB). Dr. Vallerga trained in Molecular and Cell Biology and Physiology at the University of California-Berkeley and UC-San Francisco in the Departments of Molecular Cell Biology and Pharmaceutical Chemistry, respectively. Anne Vallerga also received an MBA (high academic distinction) with a focus on Healthcare Leadership from the Dominican University of California and completed Advanced Business training at the University of California-Berkeley in the BioExecutive Institute, Haas School of Business.

VP of Finance and Principle Financial Officer

Dennis Gao

Dennis Gao joined DiaCarta in November 2022 and serves as Vice President of Finance and Principle Financial Officer. Dennis manages the Company’s accounting and finance activities and works closely with
human resources and legal. Prior to joining DiaCarta, Dennis held CFO and senior operational positions at several high-tech companies, including Halio, Avatar Integrated Systems (acquired by Siemens), ET
Healthcare, Integrated Memory Logic (acquired by MaxLinear), DemandTec (acquired by IBM) and E-Tek Dynamics (acquired by JDS Uniphase). He has extensive experience in raising capital and many other M&A
activities. He holds MBA in Finance from Indiana University Bloomington, a Master in Accounting from Devry University, and a Bachelor of Science in Economics degree from Nankai University.

Vice President of Regulatory

King Lee, Ph.D.

Dr. King Lee is serving as the Executive Director of Regulatory Affairs at Brightech International and Vice President of Regulatory Affairs of Axella Research. Both companies have been jointly working on numerous projects since 2015. Prior to that, Dr. Lee was the Vice President of Regulatory and Clinical Affairs for Cornerstone Pharmaceuticals, Inc., a company that develops novel anti-cancer agents such as Altered Energy Metabolism-Directed (AEMD) compounds that affect tumor-specific pyruvate dehydrogenase complex (PDC), since 2004. Dr. Lee was also an independent consultant to a number of companies, including ExSAR Corporation and ZYWIE LCC, providing regulatory affairs services in the development of new products for the treatment of metabolic diseases such as Tay-Sachs disease and Gaucher’s Disease. Dr. Lee is also a consultant to Pars Pharmaceuticals, which a CRO providing various services to pharmaceutical companies. Previously, he was the Vice President of Regulatory Affairs for Acorda Therapeutics, Inc. Prior to Acorda during the years 2001-2003, Dr. Lee was Executive Director of Regulatory Affairs/Quality Assurance for ATON Pharma, Inc. (acquired by Merck), and worked with drugs such as ZOLINZA™ (vorinostat) which was approved by the FDA in 2006 for the treatment of cutaneous T-cell lymphoma. Prior to ATON, Dr. Lee was the Director of Regulatory Affairs/Quality Assurance for VION Pharmaceuticals, Inc. from 1996 to 2001, responsible for Regulatory Affairs, preclincal and clinical assessments of several types of oncology products including ribonucleotide inductase inhibitors, novel alkylating agents, and biologics. He was the Manager of Regulatory Affairs/Clinical Affairs for IBEX Technologies, Inc. from 1993 to 1996, responsible for an IND and clinical development of hematological products. Prior to IBEX, Dr. Lee was with Sterling-Winthrop from 1987 to1993, where he was involved with several INDs that led to NDAs and FDA approval of drugs such as congestive heart failure products including Primacor (milirinone) and MRI contrast agents including Omniscan™ (gadodiamide). Dr. Lee began his career in the pharmaceutical industry at Wyeth in 1985. He has been an adjunct professor at Quinnipiac University since 2006, and from 1982 to 1983 was a part-time faculty member of Eastern Kentucky University. Dr. Lee has authored and co-authored over 40 publications (scientific and professional papers, books and review articles) and numerous scientific abstracts. Dr. Lee received his Ph.D. in Pharmacology from the College of Medicine of the University of Kentucky in 1983 and was certified by the Regulatory Affairs Professionals Board in 1994.

Vice President of Product Management and Marketing

Wei Liu, Ph.D., MBA

Wei has worked in research, product management, and marketing roles over his career in both big (Bio-Rad and Thermo Fisher Scientific) and small companies. He has marketed products in bio-research, environmental analysis, and molecular diagnostics fields, holding global and Asia-pacific marketing roles. Wei has earned his Ph.D. from the University of Illinois at Chicago and his MBA from the Hass School of Business, University of Berkeley. He has 14 publications and 4 patents.

Vice President, Clinical Affairs

Zheng Li, MBBS, MS

Experienced leader and Clinical Laboratory (CAP-accredited) Director with over 20 years of molecular diagnostics industry, with in-depth medical and molecular knowledge and expertise, including companion diagnostics, oncology, infectious diseases, non-invasive prenatal testing, and biomarker strategy. Strong hands-on knowledge in product development processes and quality management systems, from basic research to manufacture, FDA, and CLIA regulations. His previous positions consist of executive roles at various leading liquid biopsy/precision medicine companies such as Guardant Health and Predicine, as well as senior management positions in fortune 500 companies, Thermo Fisher, Siemens, and Novartis, etc. He had more than 10 patents and over 20 publications.

CLIA Lab Director

C. Mark Lu, M.D.

Dr. Lu is a board-certified Clinical Pathologist and Hematopathologist. He studied at Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China. He was trained at Beijing University Health Science Center, UC San Diego and Harvard University before joining UC San Francisco faculty in 2003. Currently he is the Vice Chairman of Department of Laboratory Medicine, UC San Francisco. Dr. Lu has published more than 70 peer-reviewed articles, and authored the popular «Guide to Diagnostic Tests» (2007, 2012, 2017), which has been translated into seven non-English languages. He contributes to the «Current Medical Diagnosis & Treatment» (2010-2020 eds), and five other medical textbooks. Dr. Lu represents the American Society of Hematology on the Editorial Board of the Lab Tests Online (http://labtestonline.org) , a worldwide and free online resource for the general public on medical diagnostic tests

General Manager, Asia Pacific

Effie Ho, Ph.D., MBA

Effie brought in more than 15 years industrial experience to the company including many years at J&J and Pfizer. Specialized in drug and medical device’s business development strategies and RA/Clinical Development execution in emerging healthcare markets horizontally (strategy planning, RA and Clinical planning, local partner, raising capital, execution clinical planning , regulatory approval and vertically (execution of clinical development in China, Taiwan, Korea, HK) with proven records from IP to products. Obtained M.B.A. from Penn state University, PA, USA; Postdoc at Harvard Medical School, Boston, MA, Obtained PhD from Rutgers University, NJ, USA.

Sr. Director, BD & Clinical (EU)

Dr Mauro Scimia

Mauro has a master’s degree in Medicine, from the University of Rome, School of Medicine. Mauro also learned Biostatistics, Regression Analysis, Clinical trials design and implementation at John Hopkins University through Coursera. Other education background includes several management courses like finance, marketing, leadership, and conflict resolution at various career stages. Past experiences include the following: International Marketing Manager for Menarini Diagnostics in Europe; Marketing Manager for Glaxo Pharmaceuticals in the Middle East; Country Manager Italy for NeuroMedical Systems and for Hologic; European Manager for Third Wave Technologies; HPV PapilloCheck Consultant Italy for Greiner BioOne; European Manager and Board Director for Cytocore; Reginal Business Director for Exact Sciences, Europe; Currently Strategic and Business Development for DiaCarta.

Medical & Scientific Advisors

Sir Walter Bodmer FRCPath, FRS
Professor and Department Head Cancer & Immunogenetics Laboratory

Sir Walter Bodmer FRCPath, FRS
Frank McCormick, Ph.D.
Founder, Onyx

Frank McCormick, Ph.D.
Mickey Urdea, Ph.D.
Board, Bill and Melinda Gates Foundation Diagnostic Forum

Mickey Urdea, Ph.D.
Dean Tsao, Ph.D.
Founder and Chairman, Genemed and PlexBio

Dean Tsao, Ph.D.
Anthony M. Magliocco, M.D.
Chair of Advisory Board

Anthony M. Magliocco, M.D.
Sir Walter Bodmer FRCPath, FRS

Professor and Department Head Cancer & Immunogenetics Laboratory

Sir Walter Bodmer FRCPath, FRS

Sir Walter Bodmer got his BA in mathematics (1956) and then his Ph.D. in population genetics (1959) under Sir Ronald Fisher at Cambridge University. He did his post- doctoral work in molecular biology under Dr Joshua Lederberg at Stanford and then was on the faculty of the Genetics Department in the Stanford University Medical School until 1970, ending up as a Full Professor. He returned to England in 1970 to become Professor of Genetics and head of a new department at Oxford University, and then in 1979 became Director of Research, and later Director General, of the Imperial Cancer Research Fund. Since 1996 he has been head of the cancer and immunogenetics laboratory at the Weatherall Insitute of Molecular Medicine at Oxford University, and from 1996 to 2005 was also the Principal of Hertford College, Oxford.
Walter Bodmer became a Fellow of the Royal Society in 1974, a Foreign Member of the US National Academy of Sciences in 1981 and was Knighted in 1986 for his contributions to science. In 2013 he was awarded a Royal Society Royal Medal for seminal contributions to population genetics, gene mapping and understanding of familial genetic disease. He is the recipient of more than 20 honorary degrees and is an Honorary Fellow or member of more than 15 medical and scientific societies and professional bodies. Walter Bodmer was amongst the earliest to suggest the human genome project and was the second President of HUGO, the Human Genome Organisation.
Sir Walter’s early research was in population genetics, especially the relationship between selection and linkage. He was one of the first to use computers for the simulation of population genetics models starting in 1957. On coming to Stanford he initiated work on the HLA system with Julia Bodmer and Rose Payne, leading to their discovery of what became the HLA -A locus, and also on somatic cell genetics using human-mouse hybrids. His laboratory described some of the first genetic linkages and chromosomal assignments using this technique, and, in collaboration with others, mapped the abl oncogene to chromosome 9, laying the foundations for the discovery of bcr/abl at the 9/22 translocation break point in CML.
Walter Bodmer, with Hugh McDevitt, provided the first explanation for the association of HLA determinants with disease in terms of linkage disequilibrium with functional variation in the HLA region, and then made the suggestion that, quite generally, association studies with genetic markers could be used to search for the genetic basis of multifactorial disease susceptibility. This has been the whole basis for the more recent development of whole genome association studies to discover the basis for genetic susceptibility to common diseases. His laboratory obtained the first monoclonal antibodies to HLA determinants, which have been widely used in immunological research. They were the first to clone the HLA ClassII genes and the first to map the FAP/APC gene to chromosome 5q, following which they have done many studies on mutations in the APC and other genes in colorectal cancer.
More recently, Sir Walter’s laboratory has focused its research on (the fundamental genetics and biology of colorectal cancer and their potential applications, and the characterization and population distribution of genetic diversity in the populations of the British Isles. The latter work has been supported by two successive Wellcome Trust grants and the samples collected are now being used in the WTCC2 studies. The current focus of this work is on establishing the genetic basis of a variety of normal traits, including especially facial features.
Walter Bodmer has also pioneered the hypothesis that rare variants underlie much of the inherited susceptibility to chronic diseases, using colorectal cancer as a model. His laboratory is now working with a panel of more than 100 well characterized colorectal cancer derived cell lines with a major interest in the identification and functional analysis of cancer stem cells using the colorectal cancer derived cell lines as a model, and in using enriched cancer stem cells for preclinical investigation of novel drug responses. Their research also includes studies on antibody dependent killing of colorectal cancer cells in vitro as a prelude to their clinical development for treatment of colorectal cancer and, in collaboration with the Danish Technical University, a microfluidics approach to the analysis of fresh tumor biopsies and rare circulating cancer cells in the blood.

Frank McCormick, Ph.D.

Founder, Onyx

Frank McCormick, Ph.D.

Dr. McCormick is a molecular biologist and nationally recognized research scientist in cancer biology. He currently serves as director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. He has been the David A. Wood Chair of Tumor Biology and Cancer Research in the department of microbiology and immunology at the University of California, San Francisco and an associate dean of the UCSF School of Medicine since 1997. He is also a member of the UCSF Biomedical Sciences Program and the Herbert Boyer Program in Biological Sciences. Since 1998, Prof. McCormick has served as director of the UCSF Comprehensive Cancer Center.
Prof. McCormick is a distinguished cancer researcher focused on signal transduction pathways in cancer cells, and ways of treating cancer based on these pathways. He is an expert on tumor suppressor genes and the ras pathway.
Prof. McCormick founded Onyx Pharmaceuticals in 1992 and served as the Chief Scientific Officer from 1992 to 1996. He served as Vice President of Therapeutic Research at Chiron Corporation from 1991 to 1992. Prof. McCormick was a Vice President of Discovery Research at Cetus Oncology Corporation from 1981 to 1990, Director of Molecular Biology from 1981 to 1990, and Vice President of Research from 1990 to 1991. He served a variety of senior scientist positions at several biotechnology companies and hospitals, such as Onyx Pharmaceuticals Inc., Exelixis Inc., the Jackson Laboratory, the National Cancer Institute, and Massachusetts General Hospital, Lawrence where he has been the Senior Advisor of Research and Development since 2003.
Dr. McCormick served as the President of the Board of Director’s of American Association for Cancer Research and has served several vital roles on the scientific advisory boards of the following companies: NexGenix Pharmaceuticals Holdings, Inc., Aglaia Biomedical Ventures B.V., OncoCyte Corporation, Pancreatic Cancer Action Network, Inc., Jennerex Biotherapeutics, ORCA Therapeutics B.V., Aduro BioTech, Inc., Dicerna Pharmaceuticals, Inc., Fluidigm Corporation, Iconix Pharmaceuticals, Inc., Iconix Biosciences, Inc., Sagres Discovery, Inc., KineMatik Limited, BiPar Sciences, Inc., and Portola Pharmaceuticals, Inc.
He is a Co-Founder of DNAtriX, Inc. and currently serves as its Director. Prof. McCormick has been a Director of Exelixis Inc. since July 31, 2003 and serves as a member of its Scientific Advisory Board. Prof. McCormick has served as the Director of American Association for Cancer Research since 2008.
In 2002 Prof. McCormick received the prestigious 42nd AACR G.H.A. Clowes Memorial Award for his seminal contribution to studies of the structure and function of oncogenes, which has led to a myriad of novel therapeutic approaches. Prof. McCormick has authored more than 260 scientific publications, edited five books, and holds 21 patents. He has received numerous awards in recognition of his contributions to the field of cancer research. Prof. McCormick serves on the Editorial Board of some of the most prestigious international cancer publications and serves as a board member or advisor to multiple cancer research organizations.
Prof. McCormick was a postdoctoral fellow with Dr. Allen Smith at the Imperial Cancer Research Fund in London, England, and with Professor Seymour S. Cohen at the State University of New York, Stony Brook. Prof. McCormick received his Ph.D. in biochemistry from the University of Cambridge, England in 1975 and his B.S. in biochemistry from the University of Birmingham, England in 1972.

Mickey Urdea, Ph.D.

Board, Bill and Melinda Gates Foundation Diagnostic Forum

Mickey Urdea, Ph.D.

Mickey is a world-renowned pioneer in personalized medicine. He led the development of world’s first HIV and HCV viral load tests while serving as the head of the Nucleic Acid Diagnostics business unit at Chiron. In 1998, he joined Bayer Diagnostics as Senior Vice President of Nucleic Acid Diagnostics and acting-Chief Scientific Officer of Bayer Diagnostics. Mickey left Bayer in 2000 and co-founded Tethys Bioscience in 2002, and has served as Chairman and Chief Executive Officer. Dr. Urdea received a Ph.D. in biochemistry at Washington State University and held an NIH postdoctoral fellowship at UCSF with William J. Rutter. He has published more than 185 articles and book chapters, and is an inventor of more than 100 issued and pending patents.

Dean Tsao, Ph.D.

Founder and Chairman, Genemed and PlexBio

Dean Tsao, Ph.D.

Dr. Tsao has over 30 years of extended experience in the IVD industry. He received his Ph.D. in biochemistry from the University of Colorado. He is an accomplished scientist and successful entrepreneur with an excellent track record of launching and leading new companies to grow into successful businesses. The companies he has established have developed thousands of products that are currently being used in the diagnosis and research of cancer, HIV, Down syndrome, and numerous other medical conditions. The CISH test, one of the diagnostic products developed under the leadership of Dr. Tsao, targets the protein HER-2, which is an important indicator of breast cancer. Compared to the existing diagnostic method, the CISH test kit is significantly faster, more accurate, and more cost effective. The kit has been approved by the FDA for IVD use.

Anthony M. Magliocco, M.D.

Chair of Advisory Board

Anthony M. Magliocco, M.D.

Dr Anthony (Tony) Magliocco is a Senior Member and Chair, Department of Anatomic Pathology at Moffitt Cancer Center as well as Executive Director of Esoteric Laboratory Services and the Morsani Molecular Diagnostic Laboratory, and Scientific Director of the Moffitt Tissue Core. He is Board Certified in anatomic pathology and completed a fellowship at the Fox Cancer Center and residency at the University of Calgary. Dr Magliocco has subspecialty expertise in breast, gynecological and molecular pathology and research interests in the areas of molecular predictive markers, digital analytical microscopy, and personalized medicine. He is also co-chair of pathology for the NRG cooperative clinical trials group, and was recently appointed to the NIH NCI Genitourinary Steering Committee.
Dr. Magliocco earned his M.D. at the University of Alberta, Edmonton, Canada. He completed an Anatomical Pathology Residency at the University of Calgary in the Department of Pathology at Foothills Hospital and Fellowships in Anatomical Pathology at Royal College of Physicians and Surgeons of Canada and College of American Pathologists FCAP Fellow. He completed a Post-Doctoral Fellowship in Molecular Surgical Pathology at Fox Chase Cancer Center.
In 1998, he joined the faculty at the University of Calgary, where he most recently served as Division Head of Pathology and Laboratory Medicine. He has also served as the Director of the Translational Laboratory at Tom Baker Cancer Centre and the Medical and Scientific Director of the Canadian Breast Cancer Foundation (CBCF)/Alberta Cancer Research Institute (ACRI) Biorepository in Calgary.
Dr. Magliocco has published over 100 peer-reviewed manuscripts and received numerous honors and awards including the Overall Academic Excellence Award at the University of Calgary; the Best Scientific Abstract Award at CARO; and the New Investigator Award from the Alberta Cancer Board. Dr. Magliocco has been continuously funded over the course of the past ten years through peer reviewed grants from the National Cancer Institute of Canada (NCIC) and the Alberta Cancer Board.
Dr. Magliocco’s clinical interest is in the development of novel molecular testing for integration into routine clinical service. His research focuses on understanding the molecular basis of cancer progression including the mechanisms of metastasis and development of resistance to therapeutics including the basis of radiotherapy resistance with a major focus on women’s cancers.

Certificates

Awards

CIO Applications

Top 25 Life Sciences Technology Vendors 2018

The positioning is based on an evaluation of DiaCarta’s specialty in personalized diagnostics, translational genomics and clinical sample testing services provided in both US and China.

LEARN MORE

med-tech outlook 

Top 10 In-Vitro Diagnostic Technology Solution Providers 2018 

The positioning is based on an evaluation of DiaCarta’s specialty in genomic testing for biomarkers, personalized diagnostics and clinical sample testing service provided in their CLIA-certified lab.

LEARN MORE

CIO Bulletin

One of the 30 Fastest Growing Companies of 2018

The positioning is based on DiaCarta’s revenue growth, financial status, openness to innovation, global collaboration and partnership, flagship products launching, regulatory progress and ability to forecast future business and technology trends..

LEARN MORE

The Silicon Review

50 Innovative Companies to Watch in the Year 2018

Winning a spot on this list indicates DiaCarta has distinguished itself from peers by proving itself more valuable in terms of service quality, vast customer base, innovation, and market position

Corporate Governance

X